The world has not had a new tuberculosis (TB) drug in about half a century, and then there were three. One of them, Pretomanid, was developed by non-profit organisation TB Alliance. Its President and CEO Dr Mel Spigelman gives us a peek into plans to make it more available, besides explaining why it is necessary to walk the fine line between medicine affordability and supply sustainability.

As part of a three drug regimen - Bedaquiline, pretomanid and linezolid , or BPaL as it is known, is recommended to treat highly drug-resistant forms of TB.